About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Menu
India
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Switzerland
Close
About Us
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
Our Business
Overview
Global Generics
Emerging Markets
India
Specialty and Innovation
Biosimilars
Our Adjacencies
Investors
Overview
Financials
Reports and Filings
Committees of the Board
Code of Conduct
Policies
Shareholder Information
Memorandum and Articles of Association
Employee Stock Option Schemes
News and Events
Business Responsibility
Analyst Coverage
Investor FAQs
Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
Media
Overview
Press Releases
Media Coverage
Perspectives
Media Kit
Community
Sustainability
Overview
ESG Framework
ESG Goals and Progress
Key Highlights
ESG Ratings
ESG Governance
Careers
Contact
About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
+91 22 6640 2323
info@lupin.com
News and
Events
Press Releases
Explore
April 8, 2026
Press
Release
Lupin Foundation Inaugurates Two NCD Corners in Karauli and Hindaun, Rajasthan
April 8, 2026
Press
Release
Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
April 7, 2026
Press
Release
Lupin Announces the Approval of Dapagliflozin Tablets in the United States
April 7, 2026
Press
Release
Lupin Earns Great Place To Work® Certification™ for 2026-27
April 2, 2026
Press
Release
PR - Lupin Completes Acquisition of VISUfarma
March 31, 2026
Press
Release
Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
March 25, 2026
Press
Release
Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
March 19, 2026
Press
Release
Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India
March 17, 2026
Press
Release
Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India
February 27, 2026
Press
Release
Lupin Receives EIR from US FDA for its Goa Facility
Previous
Next
Annual General Meeting
42nd Annual General Meeting – Aug 2, 2024
42nd Annual General Meeting Transcript
41st Annual General Meeting – August 3, 2023
40th Annual General Meeting — August 3, 2022
39th Annual General Meeting — August 11, 2021
Events
February 12, 2026
Q3 FY2026 Board meeting
Presentations
Lupin’s Acquisition of VISUfarma
Download
Vinita Gupta at the JP Morgan Healthcare Conference Jan 10 2023
Download
Vinita Gupta at the JP Morgan Healthcare Conference Jan 12 2022
Download
Vinita Gupta at the JP Morgan Healthcare Conference Jan 12 2021
JP Morgan Healthcare Conference
Download
JP Morgan Healthcare Conference 2020
Download
JP Morgan Healthcare Conference 2019
Download
Investor
Contacts
Shareholder Services
investorservices@lupin.com
investor.helpdesk@in.mpms.mufg.com
Investor Relations
InvestorRelations@lupin.com
Subscribe for
Investor updates
I agree and accept the
Privacy Policy
and the
Terms of Use
of this website
Submit
Product Finder
